Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs.

De Scheerder MA, Vrancken B, Dellicour S, Schlub T, Lee E, Shao W, Rutsaert S, Verhofstede C, Kerre T, Malfait T, Hemelsoet D, Coppens M, Dhondt A, De Looze D, Vermassen F, Lemey P, Palmer S, Vandekerckhove L.

Cell Host Microbe. 2019 Sep 11;26(3):347-358.e7. doi: 10.1016/j.chom.2019.08.003. Epub 2019 Aug 27.

PMID:
31471273
2.

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Depreter B, Weening KE, Vandepoele K, Essand M, De Moerloose B, Themeli M, Cloos J, Hanekamp D, Moors I, D' Hont I, Denys B, Uyttebroeck A, Van Damme A, Dedeken L, Snauwaert S, Goetgeluk G, De Munter S, Kerre T, Vandekerckhove B, Lammens T, Philippé J.

Haematologica. 2019 Aug 1. pii: haematol.2019.222612. doi: 10.3324/haematol.2019.222612. [Epub ahead of print]

3.

Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Nagler A, Labopin M, Dholaria B, Niittyvuopio R, Maertens J, Poiré X, Cornelissen J, Reményi P, Bourhis JH, Beguin Y, Malladi R, Kerre T, Schroyens W, Savani BN, Mohty M.

Blood Adv. 2019 Jul 9;3(13):1950-1960. doi: 10.1182/bloodadvances.2019000030.

4.

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.

Poirel HA, Vanspauwen M, Macq G, De Geyndt A, Maertens J, Willems E, Selleslag D, Poiré X, Theunissen K, Graux C, Kerre T, Zachée P, Meuleman N, De Becker A, Verlinden A, Van Obbergh F, Schuermans C, De Wilde V, Jaspers A, Pranger D, Deeren D, Van Riet I, Vaes E, Beguin Y; Belgian Transplant Registry and the Belgian Haematological Society’s Transplant committee.

Bone Marrow Transplant. 2019 Sep;54(9):1434-1442. doi: 10.1038/s41409-019-0458-8. Epub 2019 Jan 29.

PMID:
30696999
5.

Clinical implications of measurable residual disease in AML: Review of current evidence.

Moors I, Vandepoele K, Philippé J, Deeren D, Selleslag D, Breems D, Straetmans N, Kerre T, Denys B.

Crit Rev Oncol Hematol. 2019 Jan;133:142-148. doi: 10.1016/j.critrevonc.2018.11.010. Epub 2018 Nov 24. Review.

PMID:
30661650
6.

Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment.

Van Schandevyl S, Kerre T.

Acta Clin Belg. 2018 Nov 13:1-7. doi: 10.1080/17843286.2018.1545373. [Epub ahead of print]

PMID:
30422748
7.

Primary intestinal aspergillosis resulting in acute intestinal volvulus after autologous stem cell transplantation in a patient with relapsed non-Hodgkin lymphoma: report on a rare infectious complication and a review of the literature.

Kennes S, Van de Putte D, Van Dorpe J, Van Hende V, Kerre T, Vlummens P.

Acta Clin Belg. 2019 Oct;74(5):359-363. doi: 10.1080/17843286.2018.1522018. Epub 2018 Sep 21.

PMID:
30238855
8.

The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial.

Schoemans HM, Goris K, Van Durm R, Fieuws S, De Geest S, Pavletic SZ, Im A, Wolff D, Lee SJ, Greinix H, Duarte RF, Poiré X, Selleslag D, Lewalle P, Kerre T, Graux C, Baron F, Maertens JA, Dobbels F; EBMT Transplantation Complications Working party.

Haematologica. 2018 Oct;103(10):1698-1707. doi: 10.3324/haematol.2018.190777. Epub 2018 Jun 14.

9.

Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study.

Servais S, Baron F, Lechanteur C, Seidel L, Selleslag D, Maertens J, Baudoux E, Zachee P, Van Gelder M, Noens L, Kerre T, Lewalle P, Schroyens W, Ory A, Beguin Y.

Oncotarget. 2018 Apr 17;9(29):20590-20604. doi: 10.18632/oncotarget.25020. eCollection 2018 Apr 17.

10.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

Laureys G, Willekens B, Vanopdenbosch L, Deryck O, Selleslag D, D'Haeseleer M, De Becker A, Dubois B, Dierickx D, Perrotta G, De Wilde V, van Pesch V, Straetmans N, Dive D, Beguin Y, Van Wijmeersch B, Theunissen K, Kerre T, Van de Velde A.

Acta Neurol Belg. 2018 Jun;118(2):161-168. doi: 10.1007/s13760-018-0905-0. Epub 2018 Mar 13.

11.

Nanobody Based Dual Specific CARs.

De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K, Kerre T, Abken H, Vandekerckhove B.

Int J Mol Sci. 2018 Jan 30;19(2). pii: E403. doi: 10.3390/ijms19020403.

12.

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF.

BMJ Open. 2017 Nov 12;7(11):e017075. doi: 10.1136/bmjopen-2017-017075.

13.

The checkpoint for agonist selection precedes conventional selection in human thymus.

Verstichel G, Vermijlen D, Martens L, Goetgeluk G, Brouwer M, Thiault N, Van Caeneghem Y, De Munter S, Weening K, Bonte S, Leclercq G, Taghon T, Kerre T, Saeys Y, Van Dorpe J, Cheroutre H, Vandekerckhove B.

Sci Immunol. 2017 Feb 24;2(8). pii: eaah4232. doi: 10.1126/sciimmunol.aah4232.

14.

A Murine Intestinal Intraepithelial NKp46-Negative Innate Lymphoid Cell Population Characterized by Group 1 Properties.

Van Acker A, Gronke K, Biswas A, Martens L, Saeys Y, Filtjens J, Taveirne S, Van Ammel E, Kerre T, Matthys P, Taghon T, Vandekerckhove B, Plum J, Dunay IR, Diefenbach A, Leclercq G.

Cell Rep. 2017 May 16;19(7):1431-1443. doi: 10.1016/j.celrep.2017.04.068.

15.

Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.

Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, Bonte S, Taghon T, Leclercq G, Kerre T, Debets R, Vermijlen D, Abken H, Vandekerckhove B.

Oncoimmunology. 2017 Jan 19;6(3):e1283460. doi: 10.1080/2162402X.2017.1283460. eCollection 2017.

16.

Hereditary polycystic kidney disease is characterized by lymphopenia across all stages of kidney dysfunction: an observational study.

Van Laecke S, Kerre T, Nagler EV, Maes B, Caluwe R, Schepers E, Glorieux G, Van Biesen W, Verbeke F.

Nephrol Dial Transplant. 2018 Mar 1;33(3):489-496. doi: 10.1093/ndt/gfx040.

PMID:
28387829
17.

The Ly49E Receptor Inhibits the Immune Control of Acute Trypanosoma cruzi Infection.

Filtjens J, Coltel N, Cencig S, Taveirne S, Van Ammel E, Van Acker A, Kerre T, Matthys P, Taghon T, Vandekerckhove B, Carlier Y, Truyens C, Leclercq G.

Front Immunol. 2016 Nov 10;7:472. eCollection 2016.

18.

The role of Ly49E receptor expression on murine intraepithelial lymphocytes in intestinal cancer development and progression.

Van Acker A, Louagie E, Filtjens J, Taveirne S, Van Ammel E, Kerre T, Elewaut D, Taghon T, Vandekerckhove B, Plum J, Leclercq G.

Cancer Immunol Immunother. 2016 Nov;65(11):1365-1375. Epub 2016 Sep 1.

PMID:
27585789
19.

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.

Willemen Y, Van den Bergh JM, Bonte SM, Anguille S, Heirman C, Stein BM, Goossens H, Kerre T, Thielemans K, Peeters M, Van Tendeloo VF, Smits EL, Berneman ZN.

Oncotarget. 2016 Nov 8;7(45):73960-73970. doi: 10.18632/oncotarget.12170.

20.

The immunophenotypic fingerprint of patients with primary antibody deficiencies is partially present in their asymptomatic first-degree relatives.

Bogaert DJ, De Bruyne M, Debacker V, Depuydt P, De Preter K, Bonroy C, Philippé J, Bordon V, Lambrecht BN, Kerre T, Cerutti A, Vermaelen KY, Haerynck F, Dullaers M.

Haematologica. 2017 Jan;102(1):192-202. doi: 10.3324/haematol.2016.149112. Epub 2016 Sep 15.

21.

Expression of the inhibitory Ly49E receptor is not critically involved in the immune response against cutaneous, pulmonary or liver tumours.

Filtjens J, Keirsse J, Van Ammel E, Taveirne S, Van Acker A, Kerre T, Taghon T, Vandekerckhove B, Plum J, Van Ginderachter JA, Leclercq G.

Sci Rep. 2016 Jul 29;6:30564. doi: 10.1038/srep30564.

22.

GATA3 induces human T-cell commitment by restraining Notch activity and repressing NK-cell fate.

Van de Walle I, Dolens AC, Durinck K, De Mulder K, Van Loocke W, Damle S, Waegemans E, De Medts J, Velghe I, De Smedt M, Vandekerckhove B, Kerre T, Plum J, Leclercq G, Rothenberg EV, Van Vlierberghe P, Speleman F, Taghon T.

Nat Commun. 2016 Apr 6;7:11171. doi: 10.1038/ncomms11171.

23.

Humanized Mice to Study Human T Cell Development.

Bonte S, Snauwaert S, Vanhee S, Dolens AC, Taghon T, Vandekerckhove B, Kerre T.

Methods Mol Biol. 2016;1323:253-72. doi: 10.1007/978-1-4939-2809-5_21.

PMID:
26294414
24.

Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.

Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, Maertens J, Kerre T, Daulne C, de Bock M, Fillet M, Ory A, Willems E, Gothot A, Humblet-Baron S, Baron F.

Clin Cancer Res. 2015 Jul 15;21(14):3131-9. doi: 10.1158/1078-0432.CCR-14-3374. Epub 2015 Mar 16.

25.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.

Baron F, Zachée P, Maertens J, Kerre T, Ory A, Seidel L, Graux C, Lewalle P, Van Gelder M, Theunissen K, Willems E, Emonds MP, De Becker A, Beguin Y.

J Hematol Oncol. 2015 Feb 6;8:4. doi: 10.1186/s13045-014-0098-9.

26.

Notch3 activation is sufficient but not required for inducing human T-lineage specification.

Waegemans E, Van de Walle I, De Medts J, De Smedt M, Kerre T, Vandekerckhove B, Leclercq G, Wang T, Plum J, Taghon T.

J Immunol. 2014 Dec 15;193(12):5997-6004. doi: 10.4049/jimmunol.1400764. Epub 2014 Nov 7.

27.

In vitro human embryonic stem cell hematopoiesis mimics MYB-independent yolk sac hematopoiesis.

Vanhee S, De Mulder K, Van Caeneghem Y, Verstichel G, Van Roy N, Menten B, Velghe I, Philippé J, De Bleser D, Lambrecht BN, Taghon T, Leclercq G, Kerre T, Vandekerckhove B.

Haematologica. 2015 Feb;100(2):157-66. doi: 10.3324/haematol.2014.112144. Epub 2014 Nov 7.

28.

Ly49E expression on CD8αα-expressing intestinal intraepithelial lymphocytes plays no detectable role in the development and progression of experimentally induced inflammatory bowel diseases.

Van Acker A, Filtjens J, Van Welden S, Taveirne S, Van Ammel E, Vanhees M, Devisscher L, Kerre T, Taghon T, Vandekerckhove B, Plum J, Leclercq G.

PLoS One. 2014 Oct 13;9(10):e110015. doi: 10.1371/journal.pone.0110015. eCollection 2014. Erratum in: PLoS One. 2015;10(4):e0124464.

29.

Contribution of the Ly49E natural killer receptor in the immune response to Plasmodium berghei infection and control of hepatic parasite development.

Filtjens J, Foquet L, Taveirne S, Van Ammel E, Vanhees M, Van Acker A, Kerre T, Taghon T, Vandekerckhove B, Plum J, Van den Steen PE, Leclercq G.

PLoS One. 2014 Jan 30;9(1):e87463. doi: 10.1371/journal.pone.0087463. eCollection 2014.

30.

In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection.

Snauwaert S, Verstichel G, Bonte S, Goetgeluk G, Vanhee S, Van Caeneghem Y, De Mulder K, Heirman C, Stauss H, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Thielemans K, Kerre T, Vandekerckhove B.

Leukemia. 2014 Apr;28(4):830-41. doi: 10.1038/leu.2013.285. Epub 2013 Oct 4.

PMID:
24091848
31.

Specific Notch receptor-ligand interactions control human TCR-αβ/γδ development by inducing differential Notch signal strength.

Van de Walle I, Waegemans E, De Medts J, De Smet G, De Smedt M, Snauwaert S, Vandekerckhove B, Kerre T, Leclercq G, Plum J, Gridley T, Wang T, Koch U, Radtke F, Taghon T.

J Exp Med. 2013 Apr 8;210(4):683-97. doi: 10.1084/jem.20121798. Epub 2013 Mar 25.

32.

Can immunotherapy specifically target acute myeloid leukemic stem cells?

Snauwaert S, Vandekerckhove B, Kerre T.

Oncoimmunology. 2013 Feb 1;2(2):e22943.

33.

Abundant stage-dependent Ly49E expression by liver NK cells is not essential for their differentiation and function.

Filtjens J, Taveirne S, Van Acker A, Van Ammel E, Vanhees M, Kerre T, Taghon T, Vandekerckhove B, Plum J, Leclercq G.

J Leukoc Biol. 2013 May;93(5):699-711. doi: 10.1189/jlb.0812378. Epub 2013 Mar 8.

PMID:
23475576
34.

Differential Ly49e expression pathways in resting versus TCR-activated intraepithelial γδ T cells.

Van Den Broeck T, Van Ammel E, Delforche M, Taveirne S, Kerre T, Vandekerckhove B, Taghon T, Plum J, Leclercq G.

J Immunol. 2013 Mar 1;190(5):1982-90. doi: 10.4049/jimmunol.1200354. Epub 2013 Jan 21.

35.

Birdshot-like chorioretinopathy in common variable immunodeficiency.

de Maeyer V, Leroy BP, Kerre T, Ferdinande L, Haerynck F, De Baets F, Kestelyn P.

Retin Cases Brief Rep. 2012 Fall;6(4):358-64. doi: 10.1097/ICB.0b013e31824f71c8.

PMID:
25389930
36.

The simultaneous appearance of a nasal natural killer-cell lymphoma and acute myelogenous leukemia.

Van Crombrugge L, De Vos G, Vanclooster C, Lemmerling M, Kerre T.

B-ENT. 2012;8(1):49-52.

PMID:
22545391
37.

RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.

Snauwaert S, Vanhee S, Goetgeluk G, Verstichel G, Van Caeneghem Y, Velghe I, Philippé J, Berneman ZN, Plum J, Taghon T, Leclercq G, Thielemans K, Kerre T, Vandekerckhove B.

Haematologica. 2012 Oct;97(10):1539-47. doi: 10.3324/haematol.2012.065581. Epub 2012 Apr 24.

38.

Notch induces human T-cell receptor γδ+ thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8 double-positive pathway.

Van Coppernolle S, Vanhee S, Verstichel G, Snauwaert S, van der Spek A, Velghe I, Sinnesael M, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Kerre T, Vandekerckhove B.

Leukemia. 2012 Jan;26(1):127-38. doi: 10.1038/leu.2011.324. Epub 2011 Nov 4.

PMID:
22051534
39.

Inhibitory receptors specific for MHC class I educate murine NK cells but not CD8αα intestinal intraepithelial T lymphocytes.

Taveirne S, Filtjens J, Van Ammel E, De Colvenaer V, Kerre T, Taghon T, Vandekerckhove B, Plum J, Held W, Leclercq G.

Blood. 2011 Jul 14;118(2):339-47. doi: 10.1182/blood-2011-01-331124. Epub 2011 May 25.

PMID:
21613250
40.

T-lymphoid differentiation potential measured in vitro is higher in CD34+CD38-/lo hematopoietic stem cells from umbilical cord blood than from bone marrow and is an intrinsic property of the cells.

De Smedt M, Leclercq G, Vandekerckhove B, Kerre T, Taghon T, Plum J.

Haematologica. 2011 May;96(5):646-54. doi: 10.3324/haematol.2010.036343. Epub 2011 Feb 17.

41.

In vitro generation of immune cells from pluripotent stem cells.

Vandekerckhove B, Vanhee S, Van Coppernolle S, Snauwaert S, Velghe I, Taghon T, Leclercq G, Kerre T, Plum J.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1488-504. Review.

PMID:
21196243
42.

Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT: a single-centre experience.

Depuydt P, Kerre T, Noens L, Nollet J, Offner F, Decruyenaere J, Benoit D.

Bone Marrow Transplant. 2011 Sep;46(9):1186-91. doi: 10.1038/bmt.2010.255. Epub 2010 Nov 1.

PMID:
21042315
43.

Functionally mature CD4 and CD8 TCRalphabeta cells are generated in OP9-DL1 cultures from human CD34+ hematopoietic cells.

Van Coppernolle S, Verstichel G, Timmermans F, Velghe I, Vermijlen D, De Smedt M, Leclercq G, Plum J, Taghon T, Vandekerckhove B, Kerre T.

J Immunol. 2009 Oct 15;183(8):4859-70. doi: 10.4049/jimmunol.0900714.

44.

Generation of T cells from human embryonic stem cell-derived hematopoietic zones.

Timmermans F, Velghe I, Vanwalleghem L, De Smedt M, Van Coppernolle S, Taghon T, Moore HD, Leclercq G, Langerak AW, Kerre T, Plum J, Vandekerckhove B.

J Immunol. 2009 Jun 1;182(11):6879-88. doi: 10.4049/jimmunol.0803670.

45.

Human intrathymic development: a selective approach.

Plum J, De Smedt M, Leclercq G, Taghon T, Kerre T, Vandekerckhove B.

Semin Immunopathol. 2008 Dec;30(4):411-23. doi: 10.1007/s00281-008-0135-2. Epub 2008 Oct 17. Review.

PMID:
18925396
46.

Active form of Notch imposes T cell fate in human progenitor cells.

De Smedt M, Reynvoet K, Kerre T, Taghon T, Verhasselt B, Vandekerckhove B, Leclercq G, Plum J.

J Immunol. 2002 Sep 15;169(6):3021-9.

47.

Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34(+) cells.

Kerre TC, De Smet G, De Smedt M, Zippelius A, Pittet MJ, Langerak AW, De Bosscher J, Offner F, Vandekerckhove B, Plum J.

Blood. 2002 Mar 1;99(5):1620-6.

PMID:
11861276
48.

Both CD34+38+ and CD34+38- cells home specifically to the bone marrow of NOD/LtSZ scid/scid mice but show different kinetics in expansion.

Kerre TC, De Smet G, De Smedt M, Offner F, De Bosscher J, Plum J, Vandekerckhove B.

J Immunol. 2001 Oct 1;167(7):3692-8.

49.

Human T lymphopoiesis. In vitro and in vivo study models.

Plum J, De Smedt M, Verhasselt B, Kerre T, Vanhecke D, Vandekerckhove B, Leclercq G.

Ann N Y Acad Sci. 2000;917:724-31. Review.

PMID:
11268400
50.

Signals from the IL-9 receptor are critical for the early stages of human intrathymic T cell development.

De Smedt M, Verhasselt B, Kerre T, Vanhecke D, Naessens E, Leclercq G, Renauld JC, Van Snick J, Plum J.

J Immunol. 2000 Feb 15;164(4):1761-7.

Supplemental Content

Support Center